TerminatedPhase 3

RIvoraxaban in Mitral Stenosis

Stopped: COVID-19 has impacted our study recruitment

Iran40 participantsStarted 2019-05-22

Plain-language summary

In this randomized controlled clinical trial, patients with moderate to severe mitral valve stenosis (MS) and atrial fibrillation (AF) will be enrolled into the study.Participants will be divided into two groups based on the anticoagulation regimen type. The intervention group will receive rivaroxaban and the control group will be given warfarin. All patients will be observed closely during a period of one year. Through the follow up, embolic events and hemorrhagic complications will be recorded in both groups. In addition, patients in both group will undergo a baseline magnetic resonance imaging (MRI) and an MRI after one-year follow up, by which the silent embolic events will be compared in both groups.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provision of signed and dated informed consent form
✓. Stated willingness to comply with all study procedures and availability for the duration of the study
✓. Men and women ≥ 18 year-old
✓. Diagnosed with moderate to severe mitral stenosis who have a history of AF of any duration documented by any electrical tracing within the prior 12 months and for which anticoagulation is indicated and planned for the duration of the study.
✓. Ability to take oral medication and be willing to adhere to the rivaroxaban regimen

Exclusion criteria

✕. Left atrial clot
✕. Severe renal dysfunction (creatinine clearance \[CrCl\] \<15 mL/min), subjects with
✕. A condition associated with a high risk of bleeding
✕. Allergic to rivaroxabn/warfarin

What they're measuring

Number of participants with stroke

Timeframe: 12 months

Number of participants with systemic embolic event

Timeframe: 12 months

Trial details

NCT IDNCT03926156

SponsorRajaie Cardiovascular Medical and Research Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-05-22

View on ClinicalTrials.gov More Mitral Stenosis trials